KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine-Reference-Cited by-同舟云学术

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine

Published:2021-08-18 Issue:10 Volume:21 Page:1325-1334
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Coupez Dahna¹,Hulo Pauline¹,Touchefeu Yann¹²,Denis Marc G³,Bennouna Jaafar⁴

Affiliation:

1. Medical Oncology Department, University Hospital of Nantes, France

2. Institut des Maladies de l’Appareil Digestif, University Hospital of Nantes, France

3. Department of Biochemistry, Centre Hospitalier Universitaire Nantes, Nantes, France

4. Medical Oncology Department, Hopital Foch, Suresnes, France

Funder

funded

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2021.1967318

Reference51 articles.

1. Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts

2. Genomic Classification of Cutaneous Melanoma

3. Molecular pathogenesis and mechanisms of thyroid cancer

4. Colorectal cancer

5. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Connecting the dots: LncRNAs in the KRAS pathway and cancer;Pathology - Research and Practice;2024-10

2. Circular RNAs in the KRAS pathway: Emerging players in cancer progression;Pathology - Research and Practice;2024-04

3. Colon Cancer Cells Evade Drug Action by Enhancing Drug Metabolism;2023-12-23

4. Drug Combination Therapy for RAS-related Colorectal Cancer;PROG BIOCHEM BIOPHYS;2023

5. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study;Frontiers in Oncology;2022-09-26